指南与共识神经与头颈病理细胞病理与分子病理

头颈部癌人乳头瘤病毒检测:美国病理学家学会指南

Human Papillomavirus Testing in Head and Neck Carcinomas: Guideline From the College of American Pathologists.
指南 / 共识 · Arch Pathol Lab Med · 2017-12-18

美国病理学家学会召集头颈与分子病理及肿瘤相关专家,系统检索文献回答6个关键问题,制定头颈部癌HPV及替代标志物检测推荐。指南建议对所有新诊断口咽鳞状细胞癌用p16免疫组化(核和质70%染色阈值)检测高危HPV,不常规检测非鳞状口咽癌或非口咽癌。

要点

  • 新诊断口咽鳞癌应检测高危HPV,可用原发瘤或颈部淋巴结转移灶,p16免疫组化采用核和质70%染色阈值。
  • 非鳞状口咽癌及非口咽癌不常规检测HPV。
  • 病理报告应写明HPV阳性或p16阳性,并遵循细胞学样本及局部/远处复发标本的检测规范。

核心结论

  • 基于系统综述与专家组共识,推荐所有新诊断口咽鳞状细胞癌患者检测高危HPV,但不常规推荐其他头颈部癌检测。

研究设计与样本

  • 美国病理学家学会召集头颈病理、分子病理及外科、内科、放射肿瘤专家制定推荐,系统检索文献回答6个关键问题,推荐综合证据强度、公开征求意见反馈与专家组共识形成。

主要发现

  • 主要推荐包括对新诊断口咽鳞状细胞癌患者检测高危HPV,可取自原发肿瘤或颈部淋巴结转移灶,采用p16免疫组化,以核和质70%染色为阈值。

关键数值与推荐

  • p16免疫组化阳性判定采用核和质70%染色阈值。
  • 不常规检测非鳞状口咽癌或非口咽癌的HPV。
  • 病理报告肿瘤为HPV阳性或p16阳性。
  • 指南提供细胞学样本检测及局部复发和远处复发标本处理的规范。

临床怎么用

  • 病理科对新诊断口咽鳞状细胞癌常规开展p16免疫组化并按70%阈值判读,报告明确HPV或p16阳性状态,非口咽及非鳞状癌不常规检测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Context Human papillomavirus (HPV) is a major cause of oropharyngeal squamous cell carcinomas, and HPV (and/or surrogate marker p16) status has emerged as a prognostic marker that significantly impacts clinical management. There is no current consensus on when to test oropharyngeal squamous cell carcinomas for HPV/p16 or on which tests to choose. Objective To develop evidence-based recommendations for the testing, application, interpretation, and reporting of HPV and surrogate marker tests in head and neck carcinomas. Design The College of American Pathologists convened a panel of experts in head and neck and molecular pathology, as well as surgical, medical, and radiation oncology, to develop recommendations. A systematic review of the literature was conducted to address 6 key questions. Final recommendations were derived from strength of evidence, open comment period feedback, and expert panel consensus. Results The major recommendations include (1) testing newly diagnosed oropharyngeal squamous cell carcinoma patients for high-risk HPV, either from the primary tumor or from cervical nodal metastases, using p16 immunohistochemistry with a 70% nuclear and cytoplasmic staining cutoff, and (2) not routinely testing nonsquamous oropharyngeal carcinomas or nonoropharyngeal carcinomas for HPV. Pathologists are to report tumors as HPV positive or p16 positive. Guidelines are provided for testing cytologic samples and handling of locoregional and distant recurrence specimens. Conclusions Based on the systematic review and on expert panel consensus, high-risk HPV testing is recommended for all new oropharyngeal squamous cell carcinoma patients, but not routinely recommended for other head and neck carcinomas.

来源:Arch Pathol Lab Med,查看原文。版权归原作者所有。

引用

  1. Lewis JS, Beadle B, Bishop JA, et al. Human Papillomavirus Testing in Head and Neck Carcinomas: Guideline From the College of American Pathologists. Arch Pathol Lab Med. 2017. PMID: 29251996. doi:10.5858/arpa.2017-0286-CP

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。